Moving Medicines to Move People Reneo is focused on improving the lives of patients with rare genetic mitochondrial diseases. Learn More Our priority is to develop therapies to improve daily function and quality of life of patients living with these rare diseases. Learn More Reneo’s lead product candidate, REN001, is known to control a number… Continue reading Home
Location: United States, California, San Diego
Total raised: $145M
Investors 5
| Date | Name | Website |
| - | New Enterp... | nea.com |
| 07.07.2021 | Aisling Ca... | aislingcap... |
| - | RA Capital... | racap.com |
| - | Amzak Heal... | amzakhealt... |
| 10.12.2020 | Abingworth... | abingworth... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.01.2021 | Series B | $95M | Abingworth... |
| 20.05.2019 | Series A | $50M | New Enterp... |
Mentions in press and media 24
| Date | Title | Description |
| 28.03.2026 | OnKure to sell $150M in stock to fund drug development | Getting your Trinity Audio player ready... OnKure Therapeutics Inc. (Nasdaq: OKUR), a Boulder precision-oncology company that went public in 2024 via a merger with California-based Reneo Pharmaceuticals Inc., expects to raise about $150 mil... |
| 19.03.2026 | OnKure reports nearly $60M cash on hand as drug trials continue | Getting your Trinity Audio player ready... OnKure Therapeutics Inc. (Nasdaq: OKUR), a Boulder precision oncology company that went public in 2024 via a merger with California-based Reneo Pharmaceuticals Inc. shrank its net loss in the final... |
| 08.05.2025 | Boulder’s OnKure increased research spending in 1Q with drug trials underway | OnKure Therapeutics Inc. (Nasdaq: OKUR), a Boulder precision oncology company that went public last year via a merger with California-based Reneo Pharmaceuticals Inc., saw its net losses grow in the first quarter of 2025 as research and dev... |
| 14.03.2025 | Business | OnKure boosts R&D spending with cancer trial underway | BOULDER — OnKure Therapeutics Inc. (Nasdaq: OKUR), a Boulder precision oncology company that went public last year via a merger with California-based Re ... |
| 20.02.2025 | Germitec and Reneo: Pioneering Change in Healthcare and Real Estate | In a world where health and sustainability are paramount, two companies are making waves. Germitec and Reneo are not just players in their respective fields; they are revolutionaries. Germitec, a medical technology firm, is harnessing the p... |
| 20.02.2025 | Reneo secures €600 million capital platform for the decarbonisation of Germany’s residential real estate | Hamburg-based Reneo, a single-source solution for cost-efficient, large-scale decarbonisation of residential real estate, today announced it has amassed a €600 million capital platform to identify and realise the ecological and economic pot... |
| 07.10.2024 | Business | Boulder’s OnKure goes public with merger; key drug trial underway | OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a merger that takes OnKure public and injects $65 million into the company as it moves through a key trial for its leading bre... |
| 13.11.2023 | Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results | Topline data results from the pivotal STRIDE study are expected in December 2023 IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the developmen... |
| 31.03.2021 | Reneo Pharmaceuticals Files for $100M IPO | Reneo Pharmaceuticals, a clinical-stage pharmaceutical company, filed an initial public offering (IPO) to raise up to $100 million on March 19, which puts Reneo among life science companies to recently enter the public market. The Carmel Va... |
| 11.01.2021 | Reneo Raises $95 Million for Rare Mitochondrial Disease | Less than two years after launching its new venture with $50 million in the bank, Reneo Pharmaceuticals follows up in a $95M Series B to further its mission to treat diseases of the mitochondria... Take 1 minute to subscribe and you'll get ... |
Show more